Literature DB >> 10732760

Role and new perspectives of transforming growth factor-alpha (TGF-alpha) in adenocarcinoma of the gastro-oesophageal junction.

A D'Errico1, C Barozzi, M Fiorentino, R Carella, M Di Simone, L Ferruzzi, S Mattioli, W F Grigioni.   

Abstract

The incidence of gastro-oesophageal junction (GEJ) adenocarcinoma is increasing in Western countries and prognosis is poor since metastasis is most often present at diagnosis. We examined samples from 87 resected type II GEJ adenocarcinomas, 30 of these with endoscopic diagnostic biopsy material, to evaluate transforming growth factor alpha (TGF-a) expression and p53 overexpression by immunohistochemistry and in situ hybridization (for TGF-alpha), in relation to biological and clinical behaviour. TGF-alpha messenger RNA (mRNA) and protein were detectable in neoplastic cells in 56% and 64% cases respectively. TGF-alpha mRNA was detected in intra- and peritumoral lymphocytes and those of metastatic lymph nodes. TGF-alpha protein expression was significantly associated with tumour progression (P= 0.025) and lymph node metastasis (P < 0.05). The strong TGF-alpha expression found in neoplastic cells inside blood and lymphatic vessels and in metastatic localizations suggests that TGF-a-positive GEJ adenocarcinomas could have a more aggressive biological phenotype. The expression of TGF-alpha mRNA and protein in both inflammatory and neoplastic cells indicates that TGF-alpha is directly synthesized by both cell compartments. Finally, since TGF-alpha expression was associated with lymph node metastasis, its detection in preoperative perendoscopic biopsies might identify patients with more aggressive tumours who may need additional therapy, including neo-adjuvant treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732760      PMCID: PMC2374390          DOI: 10.1054/bjoc.1999.1013

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

Review 1.  Transforming growth factor alpha.

Authors:  R Derynck
Journal:  Cell       Date:  1988-08-26       Impact factor: 41.582

2.  Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor.

Authors:  A B Schreiber; M E Winkler; R Derynck
Journal:  Science       Date:  1986-06-06       Impact factor: 47.728

3.  Changing distribution of adenocarcinoma of the stomach.

Authors:  I M Paterson; D F Easton; C M Corbishley; J C Gazet
Journal:  Br J Surg       Date:  1987-06       Impact factor: 6.939

4.  Improved results of surgical treatment for esophageal and gastroesophageal junction carcinomas after preoperative combined chemotherapy and radiation.

Authors:  S D MacFarlane; L D Hill; P C Jolly; R A Kozarek; R P Anderson
Journal:  J Thorac Cardiovasc Surg       Date:  1988-03       Impact factor: 5.209

5.  Cardia carcinoma considered as a distinct clinical entity.

Authors:  B Husemann
Journal:  Br J Surg       Date:  1989-02       Impact factor: 6.939

6.  Cancer of the distal esophagus and cardia. Incidence, tumorous infiltration, and metastatic spread.

Authors:  H U Sons; F Borchard
Journal:  Ann Surg       Date:  1986-02       Impact factor: 12.969

7.  Adenocarcinoma of the oesophagus and of the oesophagogastric junction.

Authors:  J N Webb; A Busuttil
Journal:  Br J Surg       Date:  1978-07       Impact factor: 6.939

8.  Interactions between stromal cell--derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia.

Authors:  M Bajaj-Elliott; R Poulsom; S L Pender; N C Wathen; T T MacDonald
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  Expression of transforming growth factor alpha messenger RNA in the normal and neoplastic gastro-intestinal tract.

Authors:  L T Malden; U Novak; A W Burgess
Journal:  Int J Cancer       Date:  1989-03-15       Impact factor: 7.396

10.  Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency.

Authors:  H H Wang; D A Antonioli; H Goldman
Journal:  Hum Pathol       Date:  1986-05       Impact factor: 3.466

View more
  6 in total

Review 1.  Biomarkers of Barrett's esophagus.

Authors:  Yasser Mahrous Fouad; Ibrahim Mostafa; Reem Yehia; Hisham El-Khayat
Journal:  World J Gastrointest Pathophysiol       Date:  2014-11-15

Review 2.  Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.

Authors:  Chin-Ann J Ong; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

3.  Carcinoma associated fibroblasts (CAFs) promote breast cancer motility by suppressing mammalian Diaphanous-related formin-2 (mDia2).

Authors:  Kaitlyn M Dvorak; Krista M Pettee; Kaitlin Rubinic-Minotti; Robin Su; Andrea Nestor-Kalinoski; Kathryn M Eisenmann
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

4.  Long noncoding RNA SH3PXD2A-AS1 promotes colorectal cancer progression by regulating p53-mediated gene transcription.

Authors:  Pingfu Hou; Tian Lin; Sen Meng; Meilin Shi; Fang Chen; Tao Jiang; Zhongwei Li; Minle Li; Sufang Chu; Junnian Zheng; Jin Bai
Journal:  Int J Biol Sci       Date:  2021-05-11       Impact factor: 6.580

5.  Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women.

Authors:  Dilek Colak; Asmaa Nofal; Albandary Albakheet; Maimoona Nirmal; Hatim Jeprel; Abdelmoneim Eldali; Taher Al-Tweigeri; Asma Tulbah; Dahish Ajarim; Osama Al Malik; Mehmet S Inan; Namik Kaya; Ben H Park; Suad M Bin Amer
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

6.  GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Authors:  Romana Illig; Eckhard Klieser; Tobias Kiesslich; Daniel Neureiter
Journal:  Gastroenterol Res Pract       Date:  2013-03-20       Impact factor: 2.260

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.